AstraZeneca’s anselamimab missed the main goal in a Phase 3 AL amyloidosis trial but showed promising benefit in a defined patient subgroup.
AstraZeneca’s Experimental Therapy Stumbles In Late-Stage Study For Rare Protein Deposit Condition
Where Today's News Shapes Tomorrow
